|
|
|
| Webinar: Modular vs. Flexible Aseptic Filling Lines: Impacts on Speed, Changeovers, and Scale | As biologics manufacturing grows more complex and Annex 1 expectations evolve, facility design is becoming a key driver of aseptic success. Join Kindeva’s John Wichelt to learn how modular, purpose-built fill-finish facilities can strengthen contamination control, improve flexibility, and support growth. Through a case study, discover strategies for building scalable infrastructure that enables efficient, compliant sterile manufacturing. Click here to learn more. |
|
|
|
| Breakthrough Solutions For Patient-Centric Therapies | Webinar | Adare Pharma Solutions | Explore 3D screen printing’s potential to revolutionize pharmaceutical manufacturing with scalable, customizable, multi-drug tablets and precise, patient-centric drug release profiles. |
|
|
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | The distance between external API producers and fill-finish experts, and the commercial apparatus of their pharma customers, has lessened. Commercial evidence now starts its derivation as innovation becomes tangible material, set processes, and then product creation … at external development and manufacturing partners. Jon Williams, CEO, Lumanity, says there's a shift toward integrating development strategy and commercial decision-making earlier in the lifecycle. | |
|
|
Managing Organic Impurities And Nitrosamines In APIs | By Stefan Kettelhoit, Ph.D., and Norbert Waldöfner, Ph.D. | How API manufacturers can assess and mitigate organic impurities and nitrosamines using risk-based strategies aligned with global regulatory expectations. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
| Work With An In-Country Depot For Efficiency And Compliance | Article | By Soudeh Tehrani, Lisa Lemelin, and Anh-Thu Le, Ropack Pharma Solutions | If you’re launching an international clinical trial, consider the noteworthy benefits of partnering with an in-country depot, including increased efficiency, reduced costs, and reliable access to raw materials. |
|
|
|
| Screening For Amorphous Drug Substance | Article | Curia | Incorporate amorphous form screening early in development to unlock solubility advantages, improve bioavailability, and accelerate your path to market. |
|
|
|
|
| Outsourced Pharma Capabilities Update - ADCs | This digital event focuses on antibody-drug conjugates (ADCs) and how CDMOs support their development from early stages through clinical and commercial manufacturing. It highlights the importance of selecting the right partner for these complex therapies, including expertise in conjugation processes, scalability, regulatory needs, and integrated development services. Attendees will learn key criteria for evaluating CDMOs and how to align partnerships to accelerate ADC program success. Click here to learn more. |
|
|
|
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
